AU2016260895B2 - Treatment for multiple myeloma (MM) - Google Patents

Treatment for multiple myeloma (MM) Download PDF

Info

Publication number
AU2016260895B2
AU2016260895B2 AU2016260895A AU2016260895A AU2016260895B2 AU 2016260895 B2 AU2016260895 B2 AU 2016260895B2 AU 2016260895 A AU2016260895 A AU 2016260895A AU 2016260895 A AU2016260895 A AU 2016260895A AU 2016260895 B2 AU2016260895 B2 AU 2016260895B2
Authority
AU
Australia
Prior art keywords
seq
sequence
antibody
region
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016260895A
Other languages
English (en)
Other versions
AU2016260895A1 (en
Inventor
Jan Endell
Stefan HÄRTLE
Stéphane LECLAIR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys GmbH
Original Assignee
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH filed Critical Morphosys GmbH
Publication of AU2016260895A1 publication Critical patent/AU2016260895A1/en
Application granted granted Critical
Publication of AU2016260895B2 publication Critical patent/AU2016260895B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
AU2016260895A 2015-05-13 2016-05-13 Treatment for multiple myeloma (MM) Active AU2016260895B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15167597 2015-05-13
EP15167597.2 2015-05-13
PCT/EP2016/060810 WO2016180958A1 (en) 2015-05-13 2016-05-13 Treatment for multiple myeloma (mm)

Publications (2)

Publication Number Publication Date
AU2016260895A1 AU2016260895A1 (en) 2017-11-09
AU2016260895B2 true AU2016260895B2 (en) 2021-08-05

Family

ID=53174925

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016260895A Active AU2016260895B2 (en) 2015-05-13 2016-05-13 Treatment for multiple myeloma (MM)

Country Status (24)

Country Link
US (2) US10533057B2 (enExample)
EP (1) EP3294769B1 (enExample)
JP (2) JP7160533B2 (enExample)
KR (1) KR20180008571A (enExample)
CN (1) CN107614530A (enExample)
AU (1) AU2016260895B2 (enExample)
CA (1) CA2984464C (enExample)
CY (1) CY1123982T1 (enExample)
DK (1) DK3294769T3 (enExample)
ES (1) ES2862708T3 (enExample)
HR (1) HRP20210552T1 (enExample)
HU (1) HUE054271T2 (enExample)
IL (1) IL255552B (enExample)
LT (1) LT3294769T (enExample)
MX (1) MX380557B (enExample)
PL (1) PL3294769T3 (enExample)
PT (1) PT3294769T (enExample)
RS (1) RS61668B1 (enExample)
RU (1) RU2723047C2 (enExample)
SG (1) SG11201708691VA (enExample)
SI (1) SI3294769T1 (enExample)
SM (1) SMT202100202T1 (enExample)
WO (1) WO2016180958A1 (enExample)
ZA (1) ZA201708386B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
JP7160533B2 (ja) * 2015-05-13 2022-10-25 モルフォシス・アーゲー 多発性骨髄腫（ｍｍ）の処置
EP3484923A1 (en) 2016-07-15 2019-05-22 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
US12371506B2 (en) 2018-01-12 2025-07-29 Takeda Pharmaceutical Company Limited Subcutaneous administration of anti-CD38 antibodies
CN110144008B (zh) 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
AU2019244478B2 (en) * 2018-03-28 2025-11-06 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-CD38 antibodies
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
IL317328A (en) * 2018-12-14 2025-01-01 Morphosys Ag Antibody formulations
IL321343A (en) * 2019-01-28 2025-08-01 Sanofi Sa Methods of treating multiple myeloma
US20200308296A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012041800A1 (en) * 2010-09-27 2012-04-05 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
JP2003524587A (ja) 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
EP3312196B1 (en) * 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
EP1888647A2 (en) 2005-05-24 2008-02-20 MorphoSys AG Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
PL2860192T3 (pl) 2005-10-12 2018-03-30 Morphosys Ag Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38
PT2641601T (pt) * 2006-08-07 2016-10-14 Dana Farber Cancer Inst Inc Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em huluc63 com bortezomib
AU2007302448C1 (en) * 2006-09-26 2019-02-14 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2580243B1 (en) * 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
US9738933B2 (en) * 2012-12-05 2017-08-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS
CN103421115B (zh) * 2013-09-02 2015-06-03 东南大学 一种cd38纳米抗体及应用
EP3063173B1 (en) * 2013-10-31 2020-07-29 Sanofi Specific anti-cd38 antibodies for treating human cancers
JP6600651B2 (ja) 2014-06-16 2019-10-30 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 骨髄腫の治療
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
PE20170676A1 (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38
JP7160533B2 (ja) * 2015-05-13 2022-10-25 モルフォシス・アーゲー 多発性骨髄腫（ｍｍ）の処置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012041800A1 (en) * 2010-09-27 2012-04-05 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl

Also Published As

Publication number Publication date
CY1123982T1 (el) 2022-05-27
MX380557B (es) 2025-03-12
JP2021130668A (ja) 2021-09-09
JP7160533B2 (ja) 2022-10-25
PT3294769T (pt) 2021-04-13
DK3294769T3 (da) 2021-03-08
RU2723047C2 (ru) 2020-06-08
HUE054271T2 (hu) 2021-08-30
ES2862708T3 (es) 2021-10-07
US20200079871A1 (en) 2020-03-12
SG11201708691VA (en) 2017-11-29
ZA201708386B (en) 2019-06-26
US11591406B2 (en) 2023-02-28
EP3294769B1 (en) 2021-01-13
WO2016180958A1 (en) 2016-11-17
RS61668B1 (sr) 2021-04-29
PL3294769T3 (pl) 2021-07-05
LT3294769T (lt) 2021-04-26
AU2016260895A1 (en) 2017-11-09
RU2017137496A3 (enExample) 2019-06-13
EP3294769A1 (en) 2018-03-21
IL255552B (en) 2022-01-01
SI3294769T1 (sl) 2021-07-30
CA2984464C (en) 2023-10-10
CA2984464A1 (en) 2016-11-17
HRP20210552T1 (hr) 2021-05-14
JP2018515513A (ja) 2018-06-14
KR20180008571A (ko) 2018-01-24
US10533057B2 (en) 2020-01-14
SMT202100202T1 (it) 2021-05-07
MX2017014396A (es) 2018-03-23
US20190048091A1 (en) 2019-02-14
RU2017137496A (ru) 2019-06-13
IL255552A (en) 2018-01-31
CN107614530A (zh) 2018-01-19

Similar Documents

Publication Publication Date Title
US11591406B2 (en) Treatment for multiple myeloma (MM)
AU2018278327B2 (en) Activatable anti-pdl1 antibodies and methods of use thereof
JP6499971B2 (ja) 抗ｃｄ３８抗体及びレナリドマイドを含む組成物
AU2013322806B2 (en) Combinations and uses thereof
EP2849784A1 (en) Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
CN118949031A (zh) 用gm-csf拮抗剂治疗癌症
WO2023172906A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
KR20240117655A (ko) 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
TW202547859A (zh) 抗人類pd-l1抗體及其用途
HK1247939A1 (en) Treatment for multiple myeloma (mm)
EA051578B1 (ru) Терапия анти-cd19 в комбинации с леналидомидом для лечения лейкоза или лимфомы
CA3064588A1 (en) Activatable anti-pdl1 antibodies, and methods of use thereof
WO2025108438A1 (zh) 抗her3抗体药物偶联物和抗vegf抗体治疗肿瘤的方法
HK1210949B (zh) 组合及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)